Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer.
Adult
Aged
Breast Neoplasms
/ genetics
Computational Biology
/ methods
Female
Gene Expression Regulation, Neoplastic
/ genetics
Gene Regulatory Networks
/ genetics
Humans
MicroRNAs
/ genetics
Middle Aged
Neoplasm Recurrence, Local
/ genetics
RNA, Messenger
/ genetics
Signal Transduction
/ genetics
ras Proteins
/ genetics
RASD1
early stage breast cancer
hsa-miR-375
local control
predictive markers
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
26 11 2020
26 11 2020
Historique:
received:
20
10
2020
revised:
15
11
2020
accepted:
24
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
28
7
2021
Statut:
epublish
Résumé
In order to characterize the various subtypes of breast cancer more precisely and improve patients selection for breast conserving therapy (BCT), molecular profiling has gained importance over the past two decades. MicroRNAs, which are small non-coding RNAs, can potentially regulate numerous downstream target molecules and thereby interfere in carcinogenesis and treatment response via multiple pathways. The aim of the current two-phase study was to investigate whether hsa-miR-375-signaling through RASD1 could predict local control (LC) in early breast cancer. The patient and treatment characteristics of 81 individuals were similarly distributed between relapse ( This two-phase study demonstrates that hsa-miR-375/RASD1 signaling is able to predict local control in early breast cancer patients, which-to our knowledge-is the first clinical report on a miR combined with one of its downstream target proteins predicting LC in breast cancer.
Sections du résumé
BACKGROUND
In order to characterize the various subtypes of breast cancer more precisely and improve patients selection for breast conserving therapy (BCT), molecular profiling has gained importance over the past two decades. MicroRNAs, which are small non-coding RNAs, can potentially regulate numerous downstream target molecules and thereby interfere in carcinogenesis and treatment response via multiple pathways. The aim of the current two-phase study was to investigate whether hsa-miR-375-signaling through RASD1 could predict local control (LC) in early breast cancer.
RESULTS
The patient and treatment characteristics of 81 individuals were similarly distributed between relapse (
CONCLUSION
This two-phase study demonstrates that hsa-miR-375/RASD1 signaling is able to predict local control in early breast cancer patients, which-to our knowledge-is the first clinical report on a miR combined with one of its downstream target proteins predicting LC in breast cancer.
Identifiants
pubmed: 33255991
pii: genes11121404
doi: 10.3390/genes11121404
pmc: PMC7759924
pii:
doi:
Substances chimiques
MIRN375 microRNA, human
0
MicroRNAs
0
RASD1 protein, human
0
RNA, Messenger
0
ras Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cytogenet Genome Res. 2016;150(1):52-59
pubmed: 27846620
J Clin Oncol. 2005 Oct 1;23(28):7199-206
pubmed: 16192604
Ann Oncol. 2019 May 1;30(5):781-787
pubmed: 30887043
Cancer Res. 2010 Nov 15;70(22):9175-84
pubmed: 20978187
PLoS One. 2014 Oct 16;9(10):e109508
pubmed: 25329395
PLoS One. 2012;7(6):e39011
pubmed: 22723919
Nat Genet. 2007 Oct;39(10):1278-84
pubmed: 17893677
Clin Chem. 2013 Jun;59(6):892-902
pubmed: 23570709
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Oncogene. 2013 Feb 28;32(9):1173-82
pubmed: 22508479
Clin Epigenetics. 2016 Mar 08;8:28
pubmed: 26962366
Sci Rep. 2018 Sep 10;8(1):13522
pubmed: 30201956
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Mol Cancer Res. 2011 Jun;9(6):791-800
pubmed: 21593139
Sci Rep. 2017 Jun 9;7(1):3202
pubmed: 28600528
Eur J Cancer. 2013 Nov;49(17):3598-608
pubmed: 23968733
Cancer Res. 2005 Aug 15;65(16):7065-70
pubmed: 16103053
Diagn Pathol. 2012 Mar 22;7:31
pubmed: 22439831
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
J Neurol Sci. 2014 Apr 15;339(1-2):144-8
pubmed: 24548484
Cancer. 2002 Nov 15;95(10):2059-67
pubmed: 12412158
Breast. 2017 Dec;36:89-95
pubmed: 28988610
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W478-83
pubmed: 22573175
Cell Rep. 2019 Sep 10;28(11):2837-2850.e5
pubmed: 31509746
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Pathol Res Pract. 2020 Jan;216(1):152754
pubmed: 31787478
Strahlenther Onkol. 2012 Jun;188(6):461-3
pubmed: 22441440
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
Cancer Genet Cytogenet. 2002 Jul 15;136(2):113-20
pubmed: 12237234
Bioinformatics. 2010 Oct 1;26(19):2363-7
pubmed: 20688976
PLoS One. 2012;7(5):e36170
pubmed: 22623953
Cancer Lett. 2013 Oct 10;339(2):175-84
pubmed: 23791885
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
N Engl J Med. 2001 Nov 8;345(19):1378-87
pubmed: 11794170
J Transl Med. 2013 Mar 05;11:57
pubmed: 23497265
Neural Comput. 2006 Jun;18(6):1472-510
pubmed: 16764511
Mol Carcinog. 2018 Jul;57(7):817-830
pubmed: 29722068
PLoS One. 2014 Mar 14;9(3):e91884
pubmed: 24632820
Nat Commun. 2018 Dec 7;9(1):5228
pubmed: 30531873
PLoS One. 2012;7(11):e48692
pubmed: 23144930
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Oncogene. 2004 Jul 29;23(34):5858-63
pubmed: 15184869
Curr Mol Med. 2011 Mar;11(2):93-109
pubmed: 21342132
J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50
pubmed: 12165639